CompletedPhase 3ACTRN12606000523505

Radiotherapy in Early Breast Cancer

Trans Tasman Radiation Oncology Group (TROG) 03.05 - A phase III study of regional radiation therapy in early breast cancer to improve overall survival.

Sponsor

National Cancer Institute of Canada (NCIC)

Enrollment

1,822 participants

Start Date

Jun 3, 2003

Study Type

Interventional

Conditions

Node positive or high risk node negative early Breast Cancer

Summary

Radiotherapy to the breast reduces the risk of cancer coming back for women with early breast cancer. This international study will determine if treating a larger area with radiotherapy can further improve the results.

Eligibility

Sex: FemalesMin Age: 16 Yearss

Plain Language Summary

Simplified for easier understanding

This study looks at radiation therapy after breast-conserving surgery in women with early breast cancer who are at high risk of the cancer returning. It is for women aged 16 and older who have had lumpectomy or similar surgery and axillary node dissection. Participants must be receiving adjuvant systemic treatment and have no evidence that the cancer has spread to distant parts of the body.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Arm 2: Breast radiation plus regional radiation. A dose of 5000cGy in 25 fractons at a rate of 200cGy per day, five days a week for five weeks will be prescribed to the modified wide tangent fields (the upper 1st and 3rd interspace ipsilateral internal mammary, superclavicular and axillary nodes).

Locations(1)

Canada

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000523505